地西他滨联合改良CAG方案治疗急性红白血病4例

张琪; 杨华; 牛建花; 朱成英; 朱海燕; 姚子龙; 于力; 靖彧

doi:10.3969/j.issn.2095-5227.2013.12.011

地西他滨联合改良CAG方案治疗急性红白血病4例

Effect of decitabine in combination with modified CAG regimen in 4 cases of acute erythroleukemia

摘要

摘要: 目的了解地西他滨联合阿柔比星(Acla)+阿糖胞苷(Ara-C)+重组人粒细胞刺激因子(G-CSF)的方案(DCAG)治疗急性红白血病(AML-M6)的疗效及不良反应。方法应用地西他滨联合CAG方案化疗,治疗4例急性红白血病患者:地西他滨20 mg/m²,1次/d,5 d;重组人粒细胞刺激因子300μg,1次/d,使用时间为化疗前1 d至中性粒细胞恢复;阿糖胞苷10 mg/m²,1次/12小时,5 d;阿柔比星20 mg,第1、3、5天使用。观察疗效及不良反应。结果 4例急性红白血病患者中,2例完全缓解(CR),2例部分缓解(PR),治疗过程中不良反应轻微,病人可耐受。结论 DCAG方案治疗急性红白血病缓解率好,不良反应轻,可以作为急性红白血病诱导化疗的备选方案。

Abstract: Objective To investigate the effect and side effect of decitabine in combination with Acla + Ara-C + G-CSF regimen on acute erythroleukemia. Methods Four patients with acute erythroleukemia were treated with decitabine in combination with CAG regimen. The effect and side effect of decitabine(20 mg/m², once a day for 5 days), G-CSF(300 μg, once a day from the day before chemotherapy to leukocyte recovery), Ara-C(10 mg/m², twice a day for 5 days), Acla(20 mg on days 1, 3, and 5) were observed. Results Of the 4 cases of acute erythroleukemia, 2 were completely recovered, 2 were partially recovered with mild adverse reactions during treatment. Conclusion The effect of decitabine in combination with CAG regimen on acute erythroleukemia is good with mild adverse reactions, and can thus be used an alternative regimen for acute erythroleukemia.

HTML全文

参考文献(0)

施引文献

资源附件(0)